natgillin/translations-raw huggingface dataset:
Dosage increase and long-term use of meperidine with Aptivus, coadministered with low dose ritonavir, are not recommended due to the increased concentrations of the metabolite normeperidine which has both analgesic activity and CNS stimulant activity (e.g. seizures). 
U bolesnika liječenih Aptivusom, uz nisku dozu ritonavira ne preporučuje se istodobna dugotrajna primjena meperidina ili povišenje doza meperidina zbog povećanih koncentracija metabolita normeperidina koji ima analgetski učinak i stimulira središnji živčani sustav (npr. epileptični napadaji).
Overall population FAS 
Ukupna populacija Svi ispitanici PP
Muscle disorders 
Poremećaji mišića
Do not take products containing St John's wort (a herbal remedy for depression). 
Ne uzimajte proizvode koji sadrže gospinu travu (biljni lijek protiv depresije), jer ona može spriječiti ispravno djelovanje Aptivusa.
Depending on your liver function you may have to delay or stop Aptivus treatment - if you are currently taking products containing: - rifampicin (used to treat tuberculosis) - cisapride (used to treat stomach problems) - pimozide or sertindole (used to treat schizophrenia) - quetiapine (used to treat schizophrenia, bipolar disorder and major depressive disorder) - lurasidone (used to treat schizophrenia) - triazolam or oral midazolam (taken by mouth). 
Vaše jetre, možda ćete morati odgoditi ili prekinuti liječenje Aptivusom - ako trenutno uzimate lijekove koji sadrže: - rifampicin (primjenjuje se u liječenju tuberkuloze) - cisaprid (primjenjuje se u liječenju želučanih problema) - pimozid ili sertindol (primjenjuju se u liječenju shizofrenije) - kvetiapin (primjenjuje se u liječenju shizofrenije, bipolarnog poremećaja i velikog depresivnog poremećaja) - lurasidon (primjenjuje se u liječenju shizofrenije) - triazolam ili oralni midazolam (uzimaju se oralno).
Narcotic analgesics Methadone 5 mg QD Methadone Cmax ↓ 55% Methadone AUC ↓ 53% Methadone Cmin ↓ 50% 
Metadon Cmax ↓ 55% Metadon AUC ↓ 53% Metadon Cmin ↓ 50%
All patients * Includes patients who did not receive ENF and those who were previously treated with and continued ENF ** Mutations in HIV protease at positions L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, 58E, H69K, T74P, V82L/T, N83D or I84V ENF Enfuvirtide; TPV/r Tipranavir with ritonavir 
* Uključuje bolesnike koji nisu primali ENF i one koji su prethodno primali ENF i to su liječenje nastavili i u pokusu ** Mutacije HIV proteaze na pozicijama L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, 58E, H69K, T74P, V82L/T, N83D, ili I84V ENF enfuvirtid; TPV/r tipranavir s ritonavirom
If you miss a dose of Aptivus or ritonavir by more than 5 hours, wait and then take the next dose of Aptivus and ritonavir at the regularly scheduled time. 
Ako propustite dozu Aptivusa ili ritonavira za više od 5 sati, pričekajte i zatim uzmite sljedeću dozu Aptivusa i ritonavira u redovno vrijeme, prema režimu doziranja.
Stavudine 
Stavudin
In such cases no dosage adjustment of zidovudine can be recommended (see section 
U takvom slučaju nije potrebno podešavati dozu zidovudina (vidjeti dio 4.4).
Propyl gallate 
Lanzoprazol Pantoprazol
If your child misses a dose of Aptivus or ritonavir by more than 5 hours, wait and then give the next dose of Aptivus and ritonavir at the regularly scheduled time. 
Ako Vaše dijete propusti dozu Aptivusa ili ritonavira za više od 5 sati, neka pričeka i zatim uzme sljedeću dozu Aptivusa i ritonavira u redovno vrijeme, prema režimu doziranja.
No data are currently available on interactions of tipranavir, coadministered with low dose ritonavir, with protease inhibitors other than those listed above. 
Trenutno nisu dostupni podaci o interakcijama tipranavira s niskom dozom ritonavira, s drugim inhibitorima proteaze osim gore navedenih.
STATEMENT OF ACTIVE SUBSTANCE(S) Each soft capsule contains 250 mg tipranavir 
NAVOĐENJE DJELATNE(IH) TVARI Jedna meka kapsula sadrži 250 mg tipranavira
The concomitant use of Aptivus, co-administered with low dose ritonavir, with dihydroergotamine, ergonovine, ergotamine or methylergonovine is contraindicated due to potential serious and/or life threatening events (see section 4.3) 
Istodobna primjena Aptivusa s niskom dozom ritonavira i dihidroergotamina, ergonovina, ergotamina, ili metilergonovina je kontraindicirana zbog potencijalnih teških i/ili fatalnih događaja (vidjeti dio 4.3)
Absorption of tipranavir, co-administered with low dose ritonavir, is reduced in the presence of antacids (see section 4.5). 
Apsorpcija tipranavira s niskom dozom ritonavira je smanjena u prisustvu antacida (vidjeti dio 4.5).
It has not been shown that tipranavir is superior to these boosted comparator protease inhibitors in patients harbouring strains susceptible to these protease inhibitors. 
Nije pokazana superiornost tipranavira spram kontrolnog tretmana u bolesnika koji su imali virusne sojeve osjetljive na kontrolne inhibitore proteaze.
Therefore Aptivus, co-administered with low dose ritonavir, should be given with food. 
Stoga se Aptivus s niskom dozom ritonavira uzima zajedno s hranom.
Steady-state tipranavir/r Midazolam Cmax ↑ 3.7 fold Midazolam AUC ↑ 9.8 fold 
Tipranavir/r u stanju ravnoteže Midazolam Cmax ↑ 3,7 puta Midazolam AUC ↑ 9,8 puta
TPV/r 500/100 mg, TPV/r 750/200 mg) represented extremes of hepatic enzyme induction and inhibition and bracketed the recommended dosage of Aptivus/r. 
Ipak, rezultati mnogih od ovih ispitivanja o interakcijama mogu se ekstrapolirati u preporučeno doziranje, s obzirom da su primijenjene doze (npr. TPV/r 500/100 mg, TPV/r 750/200 mg) predstavljale ekstreme indukcije i inhibicije jetrenih enzima, te su obuhvatile preporučene doze Aptivusa/r.
Aptivus must be administered with low dose ritonavir to ensure its therapeutic effect (see section 4.2). 
Aptivus se, u svrhu osiguranja terapijskog učinka, mora primjenjivati s niskom dozom ritonavira (vidjeti dio 4.2).
Co-administration of Aptivus, coadministered with low dose ritonavir, and rosuvastatin should be initiated with the lowest dose (5 mg/day) of rosuvastatin, titrated to treatment response, and accompanied with careful clinical monitoring for rosuvastatin associated symptoms as described in the label of rosuvastatin. 
Istodobna primjena Aptivusa s niskom dozom ritonavira i rosuvastatina započinje najnižom dozom (5 mg/dan) rosuvastatina, titriranom do terapijskog odgovora, uz pažljivo kliničko praćenje radi nuspojava rosuvastatina.
Abacavir and zidovudine 
Abakavir i zidovudin
P-gp activity is significantly inhibited after the first dose, 
Aktivnost P-gp-a je značajno inhibirana nakon prve doze, ali je u stanju dinamičke ravnoteže uočena blaga indukcija.
Aptivus oral solution contains vitamin E. Your child should not take any additional vitamin E supplements. 
Vaše dijete ne smije dodatno uzimati dodatke koji sadrže vitamin E.
Do not refrigerate or freeze After first opening of the bottle, the product can be used for 60 days. 
Nakon prvog otvaranja boce, lijek se može koristiti 60 dana.
Mean decrease in viral load from baseline to week 48, according to tipranavir baseline mutation score and enfuvirtide use in RESIST patients 
Prosječno smanjenje virusnog opterećenja od početka do 48. tjedna, u odnosu na „mutacijski skor“ i primjenu enfuvirtida u bolesnika u RESIST
Posology The recommended dose for children (age 2 to 12 years) is 375 mg/m2 Aptivus co-administered with 
Preporučena doza za djecu (u dobi 2 do 12 godina) je 375 mg/m2 Aptivusa sa 150 mg/m2 ritonavira,
Induction of CYP 2C19 by tipranavir/r 
Indukcija CYP 2C19 putem tipranavira/r
Rash consists of one or more of the preferred terms of rash, drug eruption, rash macular, rash papular, erythema, rash maculo-papular, rash pruritic, and urticaria 
Jedan ili više preferiranih termina: osip, medikamentozna erupcija, makularni osip, papularni osip, eritem, makulopapularni osip, pruritički osip ili urtikarija
In the tipranavir and comparator arms median baseline CD4 cell counts were 158 and 166 cells/mm 
Medijan početnog broja CD4 stanica u ispitivanoj skupini iznosio je 158 stanica/mm
Amber glass bottle, with two-piece plastic child-resistant closure (outer shell high density polyethylene (HDPE), inner shell polypropylene resin with a foamed laminated polyethylene liner.. Each pack contains 1 bottle of 95 ml oral solution and is supplied with a clear polypropylene 5 ml oral syringe, HDPE syringe tip cap and clear LDPE bottle-syringe adapter. 
Svako pakiranje sadrži 1 bocu sa 95 ml oralne otopine, s priloženom prozirnom polipropilenskom oralnom štrcaljkom od 5 ml, HDPE zatvaračem za štrcaljku i prozirnim nastavkom za bocu i štrcaljku od polietilena niske gustoće (LDPE).
Each Aptivus capsule contains 250 mg of the active substance tipranavir. 
Jedna Aptivus kapsula sadrži 250 mg djelatne tvari, tipranavira.
Recommendations concerning co-administration 
Preporuke o istodobnoj primjeni
The concomitant use of Aptivus, co-administered with low dose ritonavir, with flecainide, propafenone or metoprolol is contraindicated (see section 4.3) 
Istodobna primjena Aptivusa s niskom dozom ritonavira i flekainida, propafenona, ili metoprolola je kontraindicirana (vidjeti dio 4.3)
Antimalarial Halofantrine Lumefantrine No interaction study performed 
Lumefantrin Nije provedeno ispitivanje interakcija
In pre- and post-natal development studies with tipranavir in rats, growth inhibition of pups was observed at maternally toxic doses approximating 0.8-fold human exposure. 
U ispitivanjima pre- i postnatalnog razvoja u štakora, sistemska izloženost toksična za majku bila je oko 20% niža od sistemske izloženosti u ljudi pri preporučenim kliničkim dozama i rezultirala je inhibicijom rasta mladunaca.
The concomitant use of Aptivus, coadministered with low dose ritonavir, with abacavir is not recommended unless there are no other available NRTIs suitable for patient management. 
Istodobna primjena Aptivusa, s niskom dozom ritonavira, i abakavira se ne preporučuje, osim ako on nije jedini NRTI prikladan za zbrinjavanje bolesnika.
The combined use of Aptivus, coadministered with low dose ritonavir, with either omeprazole or esomeprazole is not recommended (see section 4.4). 
Kombinirana primjena Aptivusa s niskom dozom ritonavira i omeprazola ili esomeprazola se ne preporučuje (vidjeti dio 4.4).
Compared to the capsules, tipranavir exposure is higher when administering the same dose as oral solution. 
U usporedbi s kapsulama, ista doza u obliku oralne otopine rezultira većom izloženošću tipranaviru.
If the co-administration with bupropion is judged unavoidable, this should be done under close clinical monitoring for bupropion efficacy, without exceeding the recommended dosage, despite the observed induction. 
Sniženje vrijednosti bupropiona u plazmi javlja se vjerojatno zbog indukcije aktivnosti CYP2B6 i UGT ritonavirom praćenje radi učinkovitosti bupropiona, bez prekoračivanja preporučenog doziranja, usprkos primijećenoj indukciji.
Inhibition of CYP 3A4 and CYP 2D6 by tipranavir/r 
Inhibicija CYP 3A4 i CYP 2D6 putem tipranavira/r
Digoxin 0.25 mg QD po 
Digoksin 0,25 mg QD p.o.
Based on theoretical considerations, The concomitant use of Aptivus, 
Temeljem teoretskih razmatranja, istodobna primjena tipranavira s
Examples include: - rifabutin and clarithromycin (antibiotics) - theophylline (used to treat asthma) - desipramine, trazodone and bupropion (used to treat depression; bupropion is also used for smoking cessation) - midazolam (when given by injection); midazolam is a sedative used to treat anxiety and to help you sleep - rosuvastatin or pravastatin (used to lower blood cholesterol) - colchicine (used to treat gout flares with normal kidney and liver function). 
Primjeri uključuju: - rifabutin i klaritromicin (antibiotici) - teofilin (primjenjuje se u liječenju astme) - desipramin, trazodon i bupropion (primjenjuju se u liječenju depresije: bupropion se također primjenjuje u prekidu pušenja) - midazolam (kada se daje injekcijskim putem); midazolam je sedativ koji se primjenjuje u liječenju anksioznosti i kao pomoć u uspavljivanju - rosuvastatin ili pravastatin (primjenjuju se u snižavanju kolesterola u krvi) - kolhicin (koji se primjenjuje u liječenju naglih pogoršanja gihta uz urednu funkciju bubrega i jetre).
Among all randomised and treated patients, the median change from baseline in HIV-1 RNA at the last measurement up to Week 48 was -0.64 log10 copies/ml in patients receiving tipranavir with ritonavir versus -0.22 log10 copies/ml in the comparator PI/ritonavir arm. 
Uzimajući u obzir sve randomizirane i liječene bolesnike medijan razlike HIV-1 RNA između zadnjeg mjerenja (najdulje nakon 48 tjedana) i vrijednosti prije početka liječenja, iznosio je -0,64 log10 kopija/ml za ispitivanu i0,22 log10 kopija/ml za kontrolnu skupinu.
The combined use of Aptivus, coadministered with low dose ritonavir, with proton pump inhibitors is not recommended (see section 4.4). 
Kombinirana primjena Aptivusa s niskom dozom ritonavira i inhibitora protonske pumpe se ne preporučuje (vidjeti dio 4.4).
Aptivus oral solution co-administered with low dose oral solution ritonavir should be taken with food (see section 5.2). 
Aptivus oralna otopina, primijenjena istodobno s niskom dozom oralne otopine ritonavira, uzima se s hranom (vidjeti dio 5.2).
With respect to mutations on codons 33, 82, 84 and 90 approximately 4% had no mutations, 24% had mutations at codons 82 (less than 1% of patients had the mutation V82L) and 90, 18% had mutations at codons 84 and 90 and 53% had at least one key mutation at codon 90. 
Na početku studija, medijan broja mutacija u genu za proteazu iznosio je 16, a medijan broja primarnih mutacija gena za proteazu - D30N, L33F/I, V46I/L, G48V, I50V, V82A/F/T/L, I84V, i L90M - iznosio je 3. S obzirom na mutacije na kodonima 33, 82, 84 i 90, oko 4% bolesnika imalo je viruse bez mutacija, 24% je imalo mutacije na kodonima 82 (manje od 1% bolesnika je imalo mutaciju V82L) i 90, 18% je imalo mutacije na kodonima 84 i 90, a 53% imalo je najmanje jednu ključnu mutaciju na kodonu 90.
If a dose is missed by less than 5 hours, the patient should be instructed to take the missed dose immediately, and then to take the next dose of Aptivus and ritonavir at the regularly scheduled time. 
U slučaju propuštanja doze za manje od 5 sati, bolesnika je potrebno uputiti da odmah uzme propuštenu dozu, te da zatim uzme sljedeću dozu Aptivusa i ritonavira u redovno vrijeme prema režimu doziranja.
The clinical relevance of this reduction in amprenavir concentrations has not been established. 
Klinički značaj ovog smanjenja koncentracija amprenavira nije utvrđen.
administered with low dose ritonavir, should be separated by at least 2 hours to avoid formulation incompatibility. 
Primjena želučanootporne formulacije didanozina i Aptivus mekih kapsula s niskom dozom ritonavira mora biti odvojena najmanje 2 sata radi izbjegavanja inkompatibilnosti formulacija.
Based on theoretical considerations tipranavir, co-administered with low dose ritonavir, is expected to increase itraconazole or ketoconazole concentrations. 
Temeljem teoretskih razmatranja, očekuje se da tipranavir s niskom dozom ritonavira povećava koncentracije itrakonazola ili ketokonazola.
Aptivus with ritonavir should not be used in treatment-naïve patients. 
Aptivus s ritonavirom se ne smije primjenjivati u bolesnika koji prethodno nisu liječeni antiretrovirusnim lijekovima.
CYP 3A4 inhibition by tipranavir/r co-administered with low dose ritonavir, with alfuzosin is contraindicated. 
CYP 3A4 inhibicija putem tipranavira/r alfuzosina je kontraindicirana.
The concomitant use of Aptivus, coadministered with low dose ritonavir with zidovudine is not recommended unless there are no other available NRTIs suitable for patient management. 
Istodobna primjena Aptivusa s niskom dozom ritonavira i zidovudina se ne preporučuje, osim ako on nije jedini NRTI prikladan za zbrinjavanje bolesnika.
No interaction study performed 
Nije provedeno ispitivanje interakcija
Tipranavir phenotypic resistance 
Fenotipska otpornost na tipranavir
Switching from Aptivus capsules to the oral solution Aptivus capsules are not interchangeable with the oral solution. 
Aptivus kapsule nisu zamjenjive s oralnom otopinom.
Lamivudine 150 mg BID (TPV/r 750/100 mg BID) 
Lamivudin 150 mg BID (TPV/r 750/100 mg BID)
Coadministration of Aptivus with ritonavir, with St. John's wort is expected to substantially decrease tipranavir and ritonavir concentrations and may result in sub-optimal levels of tipranavir and lead to loss of virologic response and possible resistance to tipranavir. 
Očekuje se da istodobna primjena gospine trave znatno smanjuje koncentracije tipranavira i ritonavira te može rezultirati nedostatnim koncentracijama tipranavira i dovesti do gubitka virusnog odgovora i moguće otpornosti na tipranavir.
Steady-state tipranavir/r Digoxin Cmax ↓ 38% Digoxin AUC ↔ 
Tipranavir/r u stanju ravnoteže Digoksin Cmax ↓ 38% Digoksin AUC ↔
No tipranavir with ritonavir dose adjustment is required. 
Nije potrebno podešavanje doze kombinacije tipranavira s ritonavirom.
In such cases no dosage adjustment of abacavir can be recommended (see section 
U takvom slučaju, ne treba prilagođavati dozu abakavira (vidjeti dio 4.4).
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. 
Tijekom antiretrovirusne terapije mogu se povećati tjelesna težina i povisiti razine lipida i glukoze u krvi (vidjeti dio 4.4).
The following medicines are not recommended: - fluticasone (used to treat asthma) - atorvastatin (used to lower blood cholesterol) - salmeterol (used to achieve long-term asthma control, bronchospasm prevention with COPD) - bosentan (used to treat pulmonary artery hypertension) - halofantrine or lumefantrine (used to treat malaria) - tolterodine (used to treat overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence)) - boceprevir and telaprevir (used to treat hepatitis C) - cobicistat and products containing cobicistat (used to increase effectiveness of HIV medicines). 
Ne preporučuju se sljedeći lijekovi: - flutikazon (primjenjuje se u liječenju astme) - atorvastatin (primjenjuje se za snižavanje kolesterola u krvi) - salmeterol (primjenjuje se za postizanje dugotrajne kontrole astme, prevenciju bronhospazma u kroničnoj opstruktivnoj bolesti pluća) - bosentan (primjenjuje se u liječenju plućne hipertenzije) - halofantrin ili lumefantrin (primjenjuju se u liječenju malarije) - tolterodin (primjenjuje se u liječenju preaktivnog mjehura (sa simptomima učestalog mokrenja,
Carbamazepine total* Cmax ↑ 13% Carbamazepine total* AUC ↑ 16% Carbamazepine total* Cmin ↑ 23% 
Antiepileptici Karbamazepin 200 mg BID Karbamazepin ukupni* Cmax ↑ 13% Karbamazepin ukupni* AUC ↑ 16% Karbamazepin ukupni * Cmin ↑ 23%
Therefore, the co-administration of tipranavir, co-administered with low dose ritonavir, with protease inhibitors is not recommended. 
Stoga se ne preporučuje istodobna primjena tipranavira s niskom dozom ritonavira, i inhibitora proteaze.
Combination of rifampicin with Aptivus with concomitant low dose ritonavir is contraindicated (see section 4.5). 
Kombinacija rifampicina s Aptivusom i niskom dozom ritonavira je kontraindicirana (vidjeti dio 4.5).
Steady-state tipranavir/r Digoxin Cmax ↓ 20% Digoxin AUC ↔ 
Tipranavir/r u stanju ravnoteže Digoksin Cmax ↓ 20% Digoksin AUC ↔
Macrogol 
Ergotamin
Co-administration of Aptivus, coadministered with low dose ritonavir, and pravastatin should be initiated with the lowest dose (10 mg/day) of pravastatin, titrated to treatment response, and accompanied with careful clinical monitoring for pravastatin associated symptoms as described in the label of pravastatin. 
Istodobna primjena Aptivusa s niskom dozom ritonavira i pravastatina počinje s najnižom dozom (10 mg/dan) pravastatina, titriranom do terapijskog odgovora, te uz pažljivo kliničko praćenje radi nuspojava pravastatina.
Co-administration of atorvastatin and Aptivus, co-administered with low dose ritonavir, is not recommended. 
Istodobna primjena atorvastatina i Aptivusa s niskom dozom ritonavira se ne preporučuje.
Increased monitoring (i.e. prior to initiation of therapy, every two weeks during the first three months of treatment, then monthly until 48 weeks, and then every eight to twelve weeks thereafter) is warranted when Aptivus and low dose ritonavir are administered to patients with elevated ASAT and ALAT levels, mild hepatic impairment, chronic hepatitis B or C, or other underlying liver disease. 
U bolesnika s povišenim vrijednostima AST/ALT, blagim oštećenjem jetre, kroničnim hepatitisom B ili C, ili drugom bolešću jetre, praćenje jetrene funkcije mora biti pojačano (tj. prije početka liječenja, svaka dva tjedna tijekom prva tri mjeseca liječenja, zatim jednom mjesečno do 48 tjedana, i nakon toga svakih osam do dvanaest tjedana).
Inhibition of CYP 2D6 by tipranavir/r 
Inhibicija CYP 2D6 putem tipranavira/r
Zidovudine Cmax ↓ 49% Zidovudine AUC ↓ 36% 
Zidovudin Cmax ↓ 49% Zidovudin AUC ↓ 36%
If the combination is nevertheless considered necessary, a monitoring of the plasma levels of amprenavir is strongly encouraged (see section 
Ako se ta kombinacija ipak smatra potrebnom, valja pratiti vrijednosti amprenavira u plazmi (vidjeti dio
Induction of CYP 1A2 by tipranavir/r 
Indukcija CYP 1A2 tipranavirom/r
Through 48 weeks of treatment, the proportion of patients in the tipranavir with ritonavir arm compared to the comparator PI/ritonavir arm with HIV-1 RNA < 400 copies/ml was 30% and 14% respectively, and with HIV-1 RNA < 50 copies/ml was 23% and 10% respectively. 
IP/ritonavir skupinu 14% dok je udio bolesnika s HIV-1 RNA <50 kopija/ml iznosio 23% za ispitivanu i 10% za kontrolnu skupinu.
Rash consists of one or more of the preferred terms of rash, drug eruption, rash macular, rash papular, erythema, rash maculo-papular, rash pruritic, and urticaria. 
Jedan ili više preferiranih termina: osip, medikamentozna erupcija, makularni osip, papularni osip, eritem, makulopapularni osip, pruritički osip ili urtikarija.
Concomitant use of Aptivus, coadministered with low dose ritonavir, and rifampicin is contraindicated (see section 4.3). 
Istodobna primjena Aptivusa s niskom dozom ritonavira i rifampicina je kontraindicirana (vidjeti dio 4.3).
Rash gamma GT increased ALAT increased 
Povišeni gama- GT Povišeni ALT Anemija
- omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole (proton pump inhibitors used to reduce the gastric acid production) - metronidazole (used to treat infections) - disulfiram (used to treat alcohol dependence) - buprenorphine/naloxone (medicines used to treat severe pain) - cyclosporin, tacrolimus, sirolimus (used to prevent organ rejection (to suppress the immune system)) - warfarin (used to treat and prevent thrombosis) - digoxin (used to treat heart arrhythmias and heart failure) - antifungal medications including fluconazole, itraconazole, ketoconazole or voriconazole 
Ne smije Vam se propisati tadalafil dok ne prođe 7 ili više dana od početka uzimanja Aptivusa. - omeprazol, esomeprazol, lanzoprazol, pantoprazol, rabeprazol (inhibitori protonske pumpe koji se primjenjuju za smanjenje proizvodnje želučane kiseline) - metronidazol (primjenuje se u liječenju infekcija) - disulfiram (primjenjuje se u liječenju ovisnosti o alkoholu) - buprenorfin/nalokson (lijekovi koji se primjenjuju za liječenje teške boli) - ciklosporin, takrolimus, sirolimus (primjenjuju se za sprječavanje odbacivanja organa (za supresiju imunološkog sustava)) - varfarin (primjenjuje se u liječenju i prevenciji tromboze) - digoksin (primjenjuje se u liječenju srčanih aritmija i zatajenja srca) - lijekovi za liječenje gljivičnih infekcija uključujući flukonazol, itrakonazol, ketokonazol ili vorikonazol
A safe and effective dose has not been established when used with Aptivus, co-administered with low dose ritonavir. 
Sigurna i učinkovita doza tadalafila kada se primjenjuje s Aptivusom uz nisku dozu ritonavira nije utvrđena.
A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function if treatment with Aptivus/ritonavir is required (see section 4.4). 
Preporučuje se sniženje doze kolhicina ili prekid liječenja kolhicinom za bolesnike s urednom funkcijom bubrega ili jetre u slučaju potrebe liječenja